Mirabegron And Ureteral Stent-related Pain (MAP) Trial
Condition: Nephrolithiasis Interventions: Drug: Mirabegron 50 MG; Drug: Placebo oral tablet Sponsors: St. Michael's Hospital, Toronto; Canadian Urological Association Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Hospitals | Kidney Stones | Pain | Research | Ureter and Renal Pelvis Cancer | Urology & Nephrology